Literature DB >> 25644543

Barriers to the universal adoption of bilateral internal mammary artery grafting.

Jeremiah Umakanthan1, Panch Jeyakumar1, Branavan Umakanthan1, Nikeshan Jeyakumar1, Nadarajah Senthilkumar1, Mathioli R Saraswathy1, Padminidevi Umakanthan1, Janani Umakanthan1, Tamoor Sial1, Sofia Abrina1, Frances M Buendia1, Irene Pan1, Ramadas K Kamath1, Canagaratnam Pathmarajah1, Kanagaratnam Sivalingam1, Shan A Nathan1, Shun K Sunder1, Tom Mahendra1, Ramanan Umakanthan2.   

Abstract

The left internal mammary artery (LIMA) graft is considered the "gold standard" of coronary artery bypass grafting (CABG). This conduit provides increased survival, symptomatic relief, increased freedom from myocardial infarction, and increased freedom from re-intervention when compared to saphenous venous grafting. It has a remarkable long term patency rate with clinical and angiographic outcomes that are unmatched by other conduits. Given the fact that patients often require more than one graft during a coronary revascularization procedure, the prospect of bilateral internal mammary artery (BIMA) grafting has been very appealing to some surgeons. BIMA grafting has been extensively studied via multiple retrospective and prospective cohort studies and findings have indicated that BIMA grafting can have an increased survival benefit when compared to LIMA grafting alone. As a result, this technique has accrued increasing popularity over the course of the last decade. Yet, questions still remain on whether BIMA grafting is the optimal treatment modality for patients in terms of long-term prognosis. There is limited data at the present time from randomized controlled trials and only 4-12% of CABGs performed today utilize BIMA grafting. Concerns regarding perioperative complications, which patient subsets are at higher risks for complications from the technique, and the technical challenges involved in utilizing and teaching the technique have limited its widespread use.
Copyright © 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bilateral internal mammary artery grafting; Coronary artery bypass grafting; Left internal mammary artery grafting

Mesh:

Year:  2015        PMID: 25644543     DOI: 10.1016/j.ijsu.2015.01.027

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  5 in total

Review 1.  Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis.

Authors:  Li Yu; Keying Zhu; Nannan Du; Yuexiu Si; Jiali Liang; Ruijing Shen; Bangsheng Chen
Journal:  J Cardiothorac Surg       Date:  2022-06-07       Impact factor: 1.522

Review 2.  Outcomes of total arterial revascularization vs conventional revascularization in patients undergoing coronary artery bypass graft surgery: A narrative review of major studies.

Authors:  Carmelo Dominici; Massimo Chello; Sahrai Saeed
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

3.  Minimally invasive direct coronary artery bypass for left anterior descending artery revascularization - analysis of 300 cases.

Authors:  Lufeng Zhang; Zhongqi Cui; Zhiming Song; Hang Yang; Yuanhao Fu; Yichen Gong; Yunpeng Ling
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2015-11-30       Impact factor: 1.195

4.  Development and Validation of a Stratification Tool for Predicting Risk of Deep Sternal Wound Infection after Coronary Artery Bypass Grafting at a Brazilian Hospital.

Authors:  Michel Pompeu Barros Oliveira Sá; Paulo Ernando Ferraz; Artur Freire Soares; Rodrigo Gusmão Albuquerque Miranda; Mayara Lopes Araújo; Frederico Vasconcelos Silva; Ricardo de Carvalho Lima
Journal:  Braz J Cardiovasc Surg       Date:  2017 Jan-Feb

5.  Bilateral Internal Mammary Artery Bypass Grafting: Sternal Wound Infection in High-Risk Population. Should Sternal Infection Scare Us?

Authors:  Justine Mafalda Ravaux; Thami Guennaoui; Christian Mélot; Peter Schraverus
Journal:  Open J Cardiovasc Surg       Date:  2018-07-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.